What should be the HPV vaccine strategy for India?
Dr Rengaswamy Sankaranarayanan - WHO-IARC, Lyon, France
7 Nov 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
4 Oct 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fall...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer ...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
28 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
The potential of PARP inhibitors in new cancer groups and in combination with ot...
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston,...
18 Jun 2019
Cervical cancer screening in North Macedonia
Prof Shaban Memeti - Institute of Public Health, Skopje, North Macedonia
5 Jun 2019
